PVTX-405: Potent Selective IKZF2 Degrader for Immunotherapy
In a groundbreaking advance in cancer immunotherapy, researchers have unveiled PVTX-405, a novel molecular glue degrader that targets IKZF2 with unprecedented selectivity and potency. This...
















